225Ac-J591

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug Name225Ac-J591
Drug Alias NameRosopatamab-225AcRosopatamab 225Ac225Ac-DOTA-J591225Ac-J591CONV 01-α +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersAnti-PSMA
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCornell University
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityCornell UniversityConvergent Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A